# Page snapshot

```yaml
- generic [active] [ref=e1]:
  - navigation [ref=e2]:
    - generic [ref=e4]:
      - link "SKYVERA" [ref=e6] [cursor=pointer]:
        - /url: /dashboard
        - generic [ref=e7]: SKYVERA
      - generic [ref=e8]:
        - link "Dashboard" [ref=e9] [cursor=pointer]:
          - /url: /dashboard
        - link "Accounts" [ref=e10] [cursor=pointer]:
          - /url: /accounts
        - link "Alerts" [ref=e11] [cursor=pointer]:
          - /url: /alerts
        - link "Scenarios" [ref=e12] [cursor=pointer]:
          - /url: /scenario
        - link "DM Strategy" [ref=e13] [cursor=pointer]:
          - /url: /dm-strategy
        - link "Ask" [ref=e14] [cursor=pointer]:
          - /url: /query
  - main [ref=e15]:
    - generic [ref=e16]:
      - generic [ref=e17]:
        - heading "DM% Strategy & Revenue Retention" [level=1] [ref=e18]
        - paragraph [ref=e19]: AI-powered recommendations to optimize decline/maintenance rates, maximize recurring revenue, and strengthen customer retention across all business units.
        - generic [ref=e20]:
          - generic [ref=e21]:
            - generic [ref=e22]: 97.4%
            - generic [ref=e23]: This Month (Jan)
          - generic [ref=e24]:
            - generic [ref=e25]: 97.4%
            - generic [ref=e26]: This Quarter (Q1'26)
          - generic [ref=e27]:
            - generic [ref=e28]: Primary
            - generic [ref=e29]: 97.4%
            - generic [ref=e30]: TTM (12 Months)
          - generic [ref=e31]:
            - generic [ref=e32]: High Impact
            - generic [ref=e33]: $1.59M
            - generic [ref=e34]: Potential ARR Recovery
          - generic [ref=e35]:
            - generic [ref=e36]: "4"
            - generic [ref=e37]: Active Recommendations
          - generic [ref=e38]:
            - generic [ref=e39]: "140"
            - generic [ref=e40]: Accounts Analyzed
        - paragraph [ref=e42]: ğŸ’¡ Recommendations are prioritized by impact and confidence
      - link "ğŸ“Š View 12-Month DM% Trend Charts Visualize retention trends with interactive charts for each business unit â†’" [ref=e44] [cursor=pointer]:
        - /url: /dm-strategy/trends
        - generic [ref=e45]:
          - generic [ref=e46]:
            - heading "ğŸ“Š View 12-Month DM% Trend Charts" [level=3] [ref=e47]
            - paragraph [ref=e48]: Visualize retention trends with interactive charts for each business unit
          - generic [ref=e49]: â†’
      - generic [ref=e52]:
        - generic [ref=e53]:
          - heading "Business Units" [level=2] [ref=e54]
          - generic [ref=e55]:
            - generic [ref=e56] [cursor=pointer]:
              - generic [ref=e57]:
                - heading "Cloudsense" [level=3] [ref=e58]
                - generic [ref=e59]: "1"
              - generic [ref=e61]:
                - generic [ref=e62]:
                  - generic [ref=e63]: This Month (Jan)
                  - generic [ref=e64]: 94.7%
                - generic [ref=e65]:
                  - generic [ref=e66]: This Quarter (Q1)
                  - generic [ref=e67]: 94.7%
                - generic [ref=e68]:
                  - generic [ref=e69]: TTM (12 Mo.)
                  - generic [ref=e70]: 94.7%
                - generic [ref=e71]: "Target: 95.0%"
              - generic [ref=e72]:
                - generic [ref=e73]: â†“
                - generic [ref=e74]: "-2.3% vs Last Quarter"
              - generic [ref=e75]:
                - generic [ref=e76]:
                  - generic [ref=e77]: ARR
                  - generic [ref=e78]: $6.4M
                - generic [ref=e79]:
                  - generic [ref=e80]: Accounts
                  - generic [ref=e81]: "65"
                - generic [ref=e82]:
                  - generic [ref=e83]: Status
                  - generic [ref=e84]: âš ï¸ Below Target
            - generic [ref=e85] [cursor=pointer]:
              - generic [ref=e86]:
                - heading "Kandy" [level=3] [ref=e87]
                - generic [ref=e88]: "2"
              - generic [ref=e90]:
                - generic [ref=e91]:
                  - generic [ref=e92]: This Month (Jan)
                  - generic [ref=e93]: 97.8%
                - generic [ref=e94]:
                  - generic [ref=e95]: This Quarter (Q1)
                  - generic [ref=e96]: 97.8%
                - generic [ref=e97]:
                  - generic [ref=e98]: TTM (12 Mo.)
                  - generic [ref=e99]: 97.8%
                - generic [ref=e100]: "Target: 95.0%"
              - generic [ref=e101]:
                - generic [ref=e102]: â†‘
                - generic [ref=e103]: +0.8% vs Last Quarter
              - generic [ref=e104]:
                - generic [ref=e105]:
                  - generic [ref=e106]: ARR
                  - generic [ref=e107]: $3.3M
                - generic [ref=e108]:
                  - generic [ref=e109]: Accounts
                  - generic [ref=e110]: "45"
                - generic [ref=e111]:
                  - generic [ref=e112]: Status
                  - generic [ref=e113]: âœ“ On Target
            - generic [ref=e114] [cursor=pointer]:
              - generic [ref=e115]:
                - heading "STL" [level=3] [ref=e116]
                - generic [ref=e117]: "1"
              - generic [ref=e119]:
                - generic [ref=e120]:
                  - generic [ref=e121]: This Month (Jan)
                  - generic [ref=e122]: 122.2%
                - generic [ref=e123]:
                  - generic [ref=e124]: This Quarter (Q1)
                  - generic [ref=e125]: 122.2%
                - generic [ref=e126]:
                  - generic [ref=e127]: TTM (12 Mo.)
                  - generic [ref=e128]: 122.2%
                - generic [ref=e129]: "Target: 95.0%"
              - generic [ref=e130]:
                - generic [ref=e131]: â†‘
                - generic [ref=e132]: +25.2% vs Last Quarter
              - generic [ref=e133]:
                - generic [ref=e134]:
                  - generic [ref=e135]: ARR
                  - generic [ref=e136]: $804K
                - generic [ref=e137]:
                  - generic [ref=e138]: Accounts
                  - generic [ref=e139]: "30"
                - generic [ref=e140]:
                  - generic [ref=e141]: Status
                  - generic [ref=e142]: âœ“ On Target
        - generic [ref=e143]:
          - generic [ref=e144]:
            - button "All 4" [ref=e145] [cursor=pointer]:
              - text: All
              - generic [ref=e146]: "4"
            - button "Critical 0" [ref=e147] [cursor=pointer]:
              - text: Critical
              - generic [ref=e148]: "0"
            - button "High Impact 1" [ref=e149] [cursor=pointer]:
              - text: High Impact
              - generic [ref=e150]: "1"
            - button "Quick Wins 0" [ref=e151] [cursor=pointer]:
              - text: Quick Wins
              - generic [ref=e152]: "0"
          - generic [ref=e153]:
            - combobox [ref=e154] [cursor=pointer]:
              - option "All Categories" [selected]
              - option "Retention"
              - option "Expansion"
              - option "Pricing"
              - option "Product"
              - option "Engagement"
              - option "Health"
            - combobox [ref=e155] [cursor=pointer]:
              - option "All Priorities" [selected]
              - option "Critical"
              - option "High"
              - option "Medium"
              - option "Low"
          - generic [ref=e156]:
            - generic [ref=e157]:
              - generic [ref=e159]: ğŸŸ  High
              - generic [ref=e160]:
                - generic [ref=e161]: Portfolio-wide
                - generic [ref=e162]: Cloudsense
              - heading "Cloudsense Product Health Investigation" [level=3] [ref=e163]
              - paragraph [ref=e164]: Cloudsense shows declining DM% trend over recent quarters. Product satisfaction may be declining.
              - generic [ref=e165]:
                - generic [ref=e166]:
                  - generic [ref=e167]: DM% Impact
                  - generic [ref=e168]: +3.0%
                - generic [ref=e169]:
                  - generic [ref=e170]: ARR Impact
                  - generic [ref=e171]: $637.0K
                - generic [ref=e172]:
                  - generic [ref=e173]: Confidence
                  - generic [ref=e174]: 70%
              - generic [ref=e175]:
                - generic [ref=e176]: ğŸ“… 90 days
                - generic [ref=e177]: âš ï¸ High Risk
                - generic [ref=e178]: ğŸ·ï¸ Product
              - generic [ref=e179]:
                - button "âœ“ Accept & Create Action" [ref=e180] [cursor=pointer]
                - button "ğŸ‘ï¸ Review Details" [ref=e181] [cursor=pointer]
                - button "â¸ï¸ Defer" [ref=e182] [cursor=pointer]
            - generic [ref=e183]:
              - generic [ref=e185]: ğŸŸ  High
              - generic [ref=e186]:
                - generic [ref=e187]: Portfolio-wide
                - generic [ref=e188]: Kandy
              - heading "Kandy Product Health Investigation" [level=3] [ref=e189]
              - paragraph [ref=e190]: Kandy shows declining DM% trend over recent quarters. Product satisfaction may be declining.
              - generic [ref=e191]:
                - generic [ref=e192]:
                  - generic [ref=e193]: DM% Impact
                  - generic [ref=e194]: +3.0%
                - generic [ref=e195]:
                  - generic [ref=e196]: ARR Impact
                  - generic [ref=e197]: $332.2K
                - generic [ref=e198]:
                  - generic [ref=e199]: Confidence
                  - generic [ref=e200]: 70%
              - generic [ref=e201]:
                - generic [ref=e202]: ğŸ“… 90 days
                - generic [ref=e203]: âš ï¸ High Risk
                - generic [ref=e204]: ğŸ·ï¸ Product
              - generic [ref=e205]:
                - button "âœ“ Accept & Create Action" [ref=e206] [cursor=pointer]
                - button "ğŸ‘ï¸ Review Details" [ref=e207] [cursor=pointer]
                - button "â¸ï¸ Defer" [ref=e208] [cursor=pointer]
            - generic [ref=e209]:
              - generic [ref=e211]: ğŸŸ¢ Medium
              - generic [ref=e212]:
                - generic [ref=e213]: Portfolio-wide
                - generic [ref=e214]: Kandy
              - heading "Kandy Upsell & Expansion Opportunity" [level=3] [ref=e215]
              - paragraph [ref=e216]: Kandy DM% is strong at 97.8%. Healthy retention creates ideal conditions for expansion.
              - generic [ref=e217]:
                - generic [ref=e218]:
                  - generic [ref=e219]: DM% Impact
                  - generic [ref=e220]: +2.0%
                - generic [ref=e221]:
                  - generic [ref=e222]: ARR Impact
                  - generic [ref=e223]: $498.4K
                - generic [ref=e224]:
                  - generic [ref=e225]: Confidence
                  - generic [ref=e226]: 70%
              - generic [ref=e227]:
                - generic [ref=e228]: ğŸ“… Q2'26
                - generic [ref=e229]: âš ï¸ Medium Risk
                - generic [ref=e230]: ğŸ·ï¸ Expansion
              - generic [ref=e231]:
                - button "âœ“ Accept & Create Action" [ref=e232] [cursor=pointer]
                - button "ğŸ‘ï¸ Review Details" [ref=e233] [cursor=pointer]
                - button "â¸ï¸ Defer" [ref=e234] [cursor=pointer]
            - generic [ref=e235]:
              - generic [ref=e237]: ğŸŸ¢ Medium
              - generic [ref=e238]:
                - generic [ref=e239]: Portfolio-wide
                - generic [ref=e240]: STL
              - heading "STL Upsell & Expansion Opportunity" [level=3] [ref=e241]
              - paragraph [ref=e242]: STL DM% is strong at 122.2%. Healthy retention creates ideal conditions for expansion.
              - generic [ref=e243]:
                - generic [ref=e244]:
                  - generic [ref=e245]: DM% Impact
                  - generic [ref=e246]: +2.0%
                - generic [ref=e247]:
                  - generic [ref=e248]: ARR Impact
                  - generic [ref=e249]: $120.6K
                - generic [ref=e250]:
                  - generic [ref=e251]: Confidence
                  - generic [ref=e252]: 70%
              - generic [ref=e253]:
                - generic [ref=e254]: ğŸ“… Q2'26
                - generic [ref=e255]: âš ï¸ Medium Risk
                - generic [ref=e256]: ğŸ·ï¸ Expansion
              - generic [ref=e257]:
                - button "âœ“ Accept & Create Action" [ref=e258] [cursor=pointer]
                - button "ğŸ‘ï¸ Review Details" [ref=e259] [cursor=pointer]
                - button "â¸ï¸ Defer" [ref=e260] [cursor=pointer]
        - generic [ref=e263]:
          - generic [ref=e264]:
            - heading "ğŸ“Š Projected Impact" [level=3] [ref=e265]
            - paragraph [ref=e266]: Based on 0 of 4 recommendations
          - generic [ref=e267]:
            - generic [ref=e268]: DM% Rate
            - generic [ref=e269]:
              - generic [ref=e270]:
                - generic [ref=e271]: Current
                - generic [ref=e272]: 104.9%
              - generic [ref=e273]: â†’
              - generic [ref=e274]:
                - generic [ref=e275]: Projected
                - generic [ref=e276]: 104.9%
          - generic [ref=e277]:
            - generic [ref=e278]: +0.0%
            - generic [ref=e279]: DM% Improvement
          - generic [ref=e280]:
            - generic [ref=e281]: Annual Recurring Revenue
            - generic [ref=e282]:
              - generic [ref=e283]:
                - generic [ref=e284]: Current
                - generic [ref=e285]: $10.50M
              - generic [ref=e286]: â†’
              - generic [ref=e287]:
                - generic [ref=e288]: Projected
                - generic [ref=e289]: $10.50M
          - generic [ref=e290]:
            - generic [ref=e291]: $0
            - generic [ref=e292]: Additional ARR
          - generic [ref=e294]:
            - generic [ref=e295]: Implementation Progress
            - generic [ref=e296]: 0/4
          - button "âš¡ Accept All High Priority" [ref=e298] [cursor=pointer]
          - generic [ref=e299]:
            - generic [ref=e300]: Key Metrics
            - generic [ref=e301]:
              - generic [ref=e302]: DM% Lift
              - generic [ref=e303]: 0.0 pts
            - generic [ref=e304]:
              - generic [ref=e305]: ARR Growth
              - generic [ref=e306]: 0.0%
            - generic [ref=e307]:
              - generic [ref=e308]: Confidence
              - generic [ref=e309]: High
      - paragraph [ref=e312]:
        - text: âœ“
        - strong [ref=e313]: "Live Data:"
        - text: Connected to DM tracker data (3 business units, 4 recommendations)
  - region "Notifications alt+T"
  - button "Open Next.js Dev Tools" [ref=e319] [cursor=pointer]:
    - img [ref=e320]
  - alert [ref=e323]
```